BR112022017724A2 - Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos - Google Patents

Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos

Info

Publication number
BR112022017724A2
BR112022017724A2 BR112022017724A BR112022017724A BR112022017724A2 BR 112022017724 A2 BR112022017724 A2 BR 112022017724A2 BR 112022017724 A BR112022017724 A BR 112022017724A BR 112022017724 A BR112022017724 A BR 112022017724A BR 112022017724 A2 BR112022017724 A2 BR 112022017724A2
Authority
BR
Brazil
Prior art keywords
braf
kras
egfr
targets
inhibitors
Prior art date
Application number
BR112022017724A
Other languages
English (en)
Inventor
K Nyati Mukesh
Bridges Alexander
Christopher Rech Jason
Taylor Watch Brennan
Original Assignee
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents
Publication of BR112022017724A2 publication Critical patent/BR112022017724A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

INIBIDORES DE EGFR, KRAS, BRAF E OUTROS ALVOS E USO DOS MESMOS. A presente invenção refere-se a compostos que são úteis no tratamento de câncer.
BR112022017724A 2020-03-05 2021-03-05 Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos BR112022017724A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062985561P 2020-03-05 2020-03-05
PCT/US2021/020990 WO2021178741A1 (en) 2020-03-05 2021-03-05 Inhibitors of egfr, kras, braf, and other targets and use of the same

Publications (1)

Publication Number Publication Date
BR112022017724A2 true BR112022017724A2 (pt) 2022-10-18

Family

ID=77612748

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017724A BR112022017724A2 (pt) 2020-03-05 2021-03-05 Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos

Country Status (11)

Country Link
US (1) US20230098205A1 (pt)
EP (1) EP4114386A4 (pt)
JP (1) JP2023515689A (pt)
KR (1) KR20220150358A (pt)
CN (1) CN115768423A (pt)
AU (1) AU2021230553A1 (pt)
BR (1) BR112022017724A2 (pt)
CA (1) CA3174538A1 (pt)
IL (1) IL296091A (pt)
MX (1) MX2022010977A (pt)
WO (1) WO2021178741A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
EP4021444A4 (en) 2019-08-29 2023-01-04 Mirati Therapeutics, Inc. G12D KRAS INHIBITORS
KR20220091480A (ko) 2019-09-24 2022-06-30 미라티 테라퓨틱스, 인크. 병용 요법
AU2020405170A1 (en) 2019-12-20 2022-06-30 Mirati Therapeutics, Inc. SOS1 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547977A (en) * 1967-10-27 1970-12-15 Velsicol Chemical Corp Novel carbanilates
GB0701955D0 (en) * 2007-02-01 2007-03-14 Glaxo Group Ltd Compounds
WO2014176475A2 (en) * 2013-04-26 2014-10-30 The Regents Of The University Of Michigan Egfr inhibitors and uses thereof
US11358965B2 (en) * 2018-02-23 2022-06-14 The Regents Of The University Of Michigan EGFR dimer disruptors and use of the same

Also Published As

Publication number Publication date
IL296091A (en) 2022-11-01
CA3174538A1 (en) 2021-09-10
WO2021178741A1 (en) 2021-09-10
KR20220150358A (ko) 2022-11-10
CN115768423A (zh) 2023-03-07
EP4114386A4 (en) 2024-07-03
US20230098205A1 (en) 2023-03-30
AU2021230553A1 (en) 2022-10-13
JP2023515689A (ja) 2023-04-13
MX2022010977A (es) 2022-12-02
EP4114386A1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
BR112022017724A2 (pt) Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos
BR112022017508A2 (pt) Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos
CY1124891T1 (el) Pd-1/pd-l1 αναστολεις
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
EA202190630A1 (ru) Способы комбинированной терапии
BR112021024108A2 (pt) Inibidores de tead e usos dos mesmos
EA202092590A1 (ru) Пиридазиноны в качестве ингибиторов parp7
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
BR112021024224A2 (pt) Inibidores de tead e usos dos mesmos
BR112023017763A2 (pt) Inibidores kras g12d
EA201992220A1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CY1125065T1 (el) Αναστολεις mcl-1
CY1120664T1 (el) Χρησεις και συνθεσεις για αντιμετωπιση διαπυητικης ιδρωταδενιτιδας (δι)
CY1124613T1 (el) Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης
BR112023009531A2 (pt) Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
EA201692285A8 (ru) Ингибиторы ezh2 для лечения лимфомы
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
CY1125158T1 (el) Συνθεσεις για την αγωγη καρκινου με εξαντληση αργινινης και ανοσο-ογκολογικους παραγοντες
EA202190749A1 (ru) Способы комбинированной терапии
CY1121334T1 (el) Αναστολεας κινασης aurora a
BR112022001341A2 (pt) Inibidores de enzima
EP3581653A3 (en) Methods and compositions for treating cancer using peptide nucleic acid-based agents

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]